Bial R&D Investments S.A.
- Address
- Avenida Da Siderurgia Nacional, Sao Mamede Do Coronado
Sponsor Overview
Specializations
Parkinson’s disease
Research activity is centred on Parkinson’s disease, with a particular focus on motor symptom progression and clinical outcomes measured through established neurological rating scales.
- Motor progression
- Movement disorder assessment
- Clinical symptom evaluation
The sponsor’s trials are aligned with the study of functional impairment in Parkinson’s disease and the monitoring of changes in daily living and motor performance.
GBA1-associated Parkinson’s disease
One major area of interest is GBA1-related Parkinson’s disease, reflecting attention to genetically defined patient groups and disease mechanisms linked to pathogenic variants.
- Genetic Parkinson’s disease
- GBA1 mutation carriers
- Inherited neurodegenerative disease
This focus places emphasis on targeted neurological research in a molecularly characterised form of Parkinson’s disease.
Neurology and movement disorders
The sponsor’s clinical research is positioned within neurology, especially the treatment and assessment of movement disorders affecting motor control and disease burden.
- Neurological therapeutics
- Motor function
- Disorder progression
Trial activity spans multiple collaborating sites across several countries, supporting research in specialised neurological care settings.
Renal impairment and pharmacokinetics
Additional clinical interest extends to renal impairment, with attention to how kidney function influences pharmacokinetics, safety, and tolerability in treated participants.
- Kidney function
- Drug disposition
- Safety evaluation
This area supports the clinical characterisation of treatment use in populations with varying degrees of renal dysfunction.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson’s Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene |  France Germany Italy Poland Portugal Spain Sweden The Netherlands | Not Recruiting |
| Evaluation of Pharmacokinetics, Safety, and Tolerability of BIA 28-6156 in Patients with Parkinson's Disease and Renal Impairment |  Hungary | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 39 sites across their trial portfolio.
Therapeutic Focus
- 1.Nervous System Diseases2 trials449 other sponsors
Partnered Research Centres
39 centres- Address
- De Boelelaan 1117, 1081 HV Amsterdam
- Address
- Via Nicolo' Giustiniani 2, 35128 Padua
- Address
- Largo Citta' D'ippocrate 1, 84131 Salerno
- Address
- Piazza Luigi Miraglia 2, 80138 Naples
- Address
- Via Bruno, 72100 Taranto
- Address
- Via Altura 3, 40139 Bologna
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Bial R&D Investments S.A..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.